Assembly Biosciences, Inc.
ASMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001426800
No open-market purchases or sales by Assembly Biosciences, Inc. insiders were filed in the last 90 days; 92 institutions reported holding it in 13F filings for Q2 2026, worth $514.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Assembly Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Assembly Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Bjorkquist Jeanette M | PFO and PAO | 14,560 | Jun 18, 2026 | 3 |
| Altig Anthony E | Director | – | Jun 5, 2026 | 1 |
| Mahony Susan | Director | – | Jun 5, 2026 | 1 |
| Consylman Gina | Director | – | Jun 5, 2026 | 1 |
| McHutchison John G | Director | 18,347 | Jun 5, 2026 | 1 |
| Okazaki Jason A | CEO and President | 163,354 | Jun 5, 2026 | 2 |
| Delaney William E IV | Chief Scientific Officer | 60,330 | Jun 5, 2026 | 2 |
| Johnson-Pratt Lisa | Director | – | Jun 5, 2026 | 1 |
| Houghton Michael | Director | 3,202Indirect | Jun 5, 2026 | 1 |
| White Nicole S | Chief Manufacturing Officer | 48,145 | Jun 5, 2026 | 2 |
| Gaggar Anuj | Chief Medical Officer | 42,688 | Jun 5, 2026 | 2 |
| Gilead Sciences, Inc. | 10% Owner | 4,977,089 | May 27, 2026 | 2 |
| Ringo William R | Director | – | Jun 9, 2025 | 0 |
| Schornstein Alexander | 10% Owner | 728,113 | Nov 26, 2024 | 0 |
| Samar Michael P. | Chief Financial Officer | 77,228 | Jul 26, 2022 | 0 |
| DiMarchi Richard D | Director | – | May 27, 2022 | 0 |
| Stamm Luisa M | Chief Medical Officer | 40,315 | Mar 31, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 23, 2024 (view filing) | Dec 19 | 4 days | Gilead Sciences, Inc.10% Owner | PPurchase | +940.5K | $21.37 | +$20.1M | +74.1%2.21M after | |
| Dec 31, 2024 (view filing) | Dec 30 | 1 day | Houghton MichaelDirector | PPurchase | +3.20K | $15.61 | +$50.0K | New position3.20K after | |
| Apr 1, 2025 (view filing) | Mar 31 | 1 day | White Nicole SChief Manufacturing Officer | SSale | −197 | $9.85 | −$1.94K | −1.7%11.7K after | |
| Apr 1, 2025 (view filing) | Mar 31 | 1 day | Okazaki Jason ACEO and President | SSale | −355 | $9.85 | −$3.50K | −2.3%14.8K after | |
| Apr 1, 2025 (view filing) | Mar 31 | 1 day | Bjorkquist Jeanette MPrincipal Accounting Officer | SSale | −180 | $9.85 | −$1.77K | −3.8%4.62K after | |
| Apr 15, 2025 (view filing) | Mar 31 | 15 daysLate | McHutchison John GDirector | SSale | −757 | $9.85 | −$7.46K | −4.0%18.3K after | |
| Oct 3, 2025 (view filing) | Aug 8 | 56 daysLate | Gilead Sciences, Inc.10% Owner | PPurchase | +2.30M | – | – | +103.9%4.51M after | |
| Oct 3, 2025 (view filing) | Aug 8 | 56 daysLate | Gilead Sciences, Inc.10% Owner | PPurchase | +2.30M | – | – | –1.15M after | Derivative2 lots |
| Mar 31, 2026 (view filing) | Mar 30 | 1 day | White Nicole SChief Manufacturing Officer | SSale | −197 | $26.69 | −$5.26K | −0.5%37.5K after | 2 lots |
| Mar 31, 2026 (view filing) | Mar 30 | 1 day | Bjorkquist Jeanette MPFO and PAO | SSale | −328 | $26.69 | −$8.75K | −2.9%11.1K after | 2 lots |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Bjorkquist Jeanette MPFO and PAO | SSale | −29 | $23.25 | −$674.25 | −0.2%14.6K after |